Biblio Discovery — Demo Discovery Service

4 results for "Birgit S. Geurts"

Showing 1–4 · 0.37 seconds · RSS

  1. Journal Article

    The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)

    Soemeya F. Haj Mohammad; Hans J.L. Timmer; Laurien J. Zeverijn et al.

    Acta Oncologica, Vol. 63 No. 1 · 2024 · English · DOAJ Scopus

    Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer. Patients: Patients…

  2. Journal Article Full text

    γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

    Natasja L. De Vries; Joris van de Haar; Vivien Veninga et al.

    Nature · 2023 · English · OpenAlex Scopus

    Abstract DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) 1,2 . Here, in contrast to other cancer types 3–5 , we observed that 20 out of 21 (95%) MMR-d cancers with…

  3. Journal Article

    Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context

    Karlijn Verkerk; Birgit S. Geurts; Laurien J. Zeverijn et al.

    The Lancet Regional Health. Europe, Vol. 39 · 2024 · English · DOAJ Scopus

    Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD from PD-1 blocker cemiplimab in patients with…

  4. Journal Article

    Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

    Birgit S. Geurts; Thomas W. Battaglia; J. Maxime van Berge Henegouwen et al.

    BMC Cancer, Vol. 23 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP). This is a clinical study in which patients are…